Development Agreement And Additional Equity Investment By Staidson For Treatment Of Covid-19

Inflarx NV

21/12/2022 12:35

Dec 21 (Reuters) - Staidson Beijing BioPharmaceuticals
Co Ltd  300204.SZ :
    * INFLARX ANNOUNCES AMENDMENT OF CO-DEVELOPMENT AGREEMENT
AND
ADDITIONAL EQUITY INVESTMENT BY STAIDSON IN CONNECTION WITH
REGULATORY FILING IN CHINA FOR ANTI-C5A-ANTIBODY FOR TREATMENT
OF COVID-19
    * INFLARX WILL RECEIVE 10% ROYALTIES ON NET SALES OF BDB-001
FOR
TREATMENT OF COVID-19 IN CHINA
    * WILL PROVIDE ACCESS TO CERTAIN CLINICAL, MANUFACTURING &
REGULATORY DOCUMENTATION FOR VILOBELIMAB TO FACILITATE STS'S 
FILINGS IN CHINA
    * STS PLANS TO REQUEST REGULATORY APPROVAL IN CHINA FOR ITS
OWN
ANTI-C5A-ANTIBODY BDB-001 FOR TREATMENT OF COVID-19
    * STS TO MAKE AN ADDITIONAL USD 2.5 MILLION INVESTMENT IN
INFLARX
AT A PRICE OF USD 5.00 PER SHARE
    * OPTION FOR INFLARX TO REQUEST STS MAKES A FURTHER USD 7.5
MILLION INVESTMENT IN INFLARX

Source text for Eikon:  ID:nGNX1jcNtw 
Further company coverage:  300204.SZ 
 ((Reuters.Briefs@thomsonreuters.com))